Univariate and multivariate analysis for remission duration (evaluable patients)
Prognostic factor . | Univariate . | Multivariate . | ||
---|---|---|---|---|
P-value . | N . | Risk ratio . | P-value . | |
Age (y)6-150 | .2987 | |||
< 45 | ||||
> 45 | ||||
Baseline WBC (cells/μL)6-150 | .2933 | |||
< 5000 | ||||
> 5000 | ||||
Sex | .6741 | |||
Female | ||||
Male | ||||
Relapse status group | .0153 | 38 | 2.42 | .0153 |
Newly diagnosed | ||||
Relapse (group 1) | ||||
Relapse (group 2) | ||||
Prior oral ATRA | .1741 | |||
No | ||||
Yes | ||||
Prior ATRA syndrome | .0063 | |||
No | ||||
Yes | ||||
Current ATRA syndrome | .9923 | |||
No | ||||
Yes | ||||
Baseline performance status | .1750 | |||
Intubation | .9928 | |||
No | ||||
Yes | ||||
DIC | .0465 | |||
No | ||||
Yes |
Prognostic factor . | Univariate . | Multivariate . | ||
---|---|---|---|---|
P-value . | N . | Risk ratio . | P-value . | |
Age (y)6-150 | .2987 | |||
< 45 | ||||
> 45 | ||||
Baseline WBC (cells/μL)6-150 | .2933 | |||
< 5000 | ||||
> 5000 | ||||
Sex | .6741 | |||
Female | ||||
Male | ||||
Relapse status group | .0153 | 38 | 2.42 | .0153 |
Newly diagnosed | ||||
Relapse (group 1) | ||||
Relapse (group 2) | ||||
Prior oral ATRA | .1741 | |||
No | ||||
Yes | ||||
Prior ATRA syndrome | .0063 | |||
No | ||||
Yes | ||||
Current ATRA syndrome | .9923 | |||
No | ||||
Yes | ||||
Baseline performance status | .1750 | |||
Intubation | .9928 | |||
No | ||||
Yes | ||||
DIC | .0465 | |||
No | ||||
Yes |
See Table 5 for abbreviations.
Age as a continuous parameter P = .2453; WBC as a continuous parameter P = .3126.